




		EMLc	ATC codes: L01DB02
Indication	Acute myeloid leukaemia with recurrent genetic abnormalities	ICD11 code: 2B30.0	
INN	Daunorubicin		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection ; 20 mg in vial (as hydrochloride) powder for injection ; 2 mg per mL in vial (as hydrochloride) ; 5 mg per mL in vial (as hydrochloride)		
EML status history	First added in 1999 (TRS 895) Changed in 2002 (TRS 914) Changed in 2007 (TRS 950) Changed in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents.</a> 		
Tags	<a href="#">Cancer</a>		
Wikipedia	<a href="#">Daunorubicin</a> 		
DrugBank	<a href="#">Daunorubicin</a> 		

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.

